NVCR Stock Overview
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NovoCure Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.05 |
| 52 Week High | US$83.60 |
| 52 Week Low | US$10.87 |
| Beta | 0.43 |
| 1 Month Change | -12.81% |
| 3 Month Change | -16.90% |
| 1 Year Change | -81.12% |
| 3 Year Change | -93.99% |
| 5 Year Change | -73.29% |
| Change since IPO | -34.08% |
Recent News & Updates
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
Apr 08
NovoCure: Sell The METIS-Inspired Rally
Mar 28Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio
Mar 03Recent updates
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
Apr 08NovoCure: Sell The METIS-Inspired Rally
Mar 28Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio
Mar 03NovoCure: Stay Cautious Amid Positive Signs
Jan 19Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Nov 16Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?
Aug 13Is NovoCure (NASDAQ:NVCR) A Risky Investment?
May 15A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)
Apr 24Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching
Feb 10Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Jan 16NovoCure: See Past Market Myopia And Buy The Dip
Sep 27Novocure creates new CNS focused franchise to renew growth in brain cancer business
Sep 21Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Sep 09NovoCure: Does The Reward Outweigh The Risk? I Believe So
Sep 09NovoCure Q2 2022 Earnings Preview
Jul 27Is NovoCure (NASDAQ:NVCR) Using Too Much Debt?
May 28NovoCure: A Stalwart With More Upsides
May 09NovoCure: Overview Of The GBM Business
Feb 28Health Check: How Prudently Does NovoCure (NASDAQ:NVCR) Use Debt?
Feb 14NovoCure: Time For A Cure
Jan 01NovoCure: Threshold Of Greatness
Nov 30Shareholder Returns
| NVCR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -17.6% | -4.1% | -3.7% |
| 1Y | -81.1% | -2.2% | 20.5% |
Return vs Industry: NVCR underperformed the US Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: NVCR underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| NVCR volatility | |
|---|---|
| NVCR Average Weekly Movement | 10.8% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NVCR's share price has been volatile over the past 3 months.
Volatility Over Time: NVCR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,453 | Asaf Danziger | www.novocure.com |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited Fundamentals Summary
| NVCR fundamental statistics | |
|---|---|
| Market cap | US$1.34b |
| Earnings (TTM) | -US$207.04m |
| Revenue (TTM) | US$509.34m |
2.5x
P/S Ratio-6.3x
P/E RatioIs NVCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVCR income statement (TTM) | |
|---|---|
| Revenue | US$509.34m |
| Cost of Revenue | US$127.54m |
| Gross Profit | US$381.80m |
| Other Expenses | US$588.85m |
| Earnings | -US$207.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -1.92 |
| Gross Margin | 74.96% |
| Net Profit Margin | -40.65% |
| Debt/Equity Ratio | 156.9% |
How did NVCR perform over the long term?
See historical performance and comparison